. The results showed that in this clinical trial, Tangning Tongluo tablet showed more significant efficacy advantages compared with calcium dobesilate capsule, the only approved chemical for the treatment of diabetes retinopathy.
Specifically, Tangning Tongluo can improve the best corrected visual acuity (BCVA) and the number of letters recognized in patients with diabetes retinopathy, which is significantly better than the calcium dobesilate capsule (dasmin) group, and can reverse the pathological changes of fundus blood vessels in patients with diabetes retinopathy. The overall safety is good. Fundus photography shows that Tangning Tongluo can reduce fundus microangioma, reduce exudation, reduce microcirculation congestion and improve microcirculation.
In February, 2021, the State Administration of traditional Chinese Medicine issued a notice on the project approval plan for the special subject of scientific and technological research of traditional Chinese medicine in 2021, and the multi center clinical research and mechanism discussion subject of Tangning Tongluo tablet for the prevention and treatment of diabetes and retinal complications was officially approved Guizhou Bailing Group Pharmaceutical Co.Ltd(002424) as the project undertaking unit, it immediately started the work. As of April 30, 2022, a total of 20 hospitals across the country had passed the ethical review and signed contracts.
“Compared with other complications, the research of sugar net treatment is more intuitive. The lesions of fundus can be seen very clearly through fundus photography, such as retinal hemorrhage, exudation, microangioma, neovascularization and other indicators can be presented objectively and analyzed quantitatively.” Professor duanjunguo, the leader of Ophthalmology of traditional Chinese medicine, a key discipline of the State Administration of traditional Chinese medicine, and the president of Chengdu Yinhai ophthalmology hospital of traditional Chinese medicine, said, “the conclusion reached through scientific and objective indicators is excellent, which can objectively reflect the curative effect of Tangning Tongluo on diabetes retinopathy.”
Guizhou Bailing Group Pharmaceutical Co.Ltd(002424) Chairman Jiang Wei said that after years of scientific research and clinical accumulation, the results of the sugar net clinical trial fully met expectations. Over the past years, Tangning Tongluo has made positive achievements in a number of animal experiments and clinical applications. The difference is that in the human clinical trial of the national scientific research project, the effectiveness of Tangning Tongluo in the treatment and reversal of sugar net complications has again obtained key evidence, which is mutually confirmed with the previous research results, which is of great significance to improve the quality of life of sugar net patients and avoid blindness.
